432 related articles for article (PubMed ID: 34557197)
1. The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab
Baysal H; De Pauw I; Zaryouh H; Peeters M; Vermorken JB; Lardon F; De Waele J; Wouters A
Front Immunol; 2021; 12():737311. PubMed ID: 34557197
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status.
Baysal H; De Pauw I; Zaryouh H; De Waele J; Peeters M; Pauwels P; Vermorken JB; Smits E; Lardon F; Jacobs J; Wouters A
Br J Cancer; 2020 Sep; 123(5):752-761. PubMed ID: 32541873
[TBL] [Abstract][Full Text] [Related]
3. Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells.
Friedman J; Padget M; Lee J; Schlom J; Hodge J; Allen C
Oral Oncol; 2019 Mar; 90():38-44. PubMed ID: 30846174
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
5. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
Fujii R; Schlom J; Hodge JW
J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Specific Antibody, Cetuximab, Enhances the
Jin WJ; Erbe AK; Schwarz CN; Jaquish AA; Anderson BR; Sriramaneni RN; Jagodinsky JC; Bates AM; Clark PA; Le T; Lan KH; Chen Y; Kim K; Morris ZS
Front Immunol; 2020; 11():591139. PubMed ID: 33281820
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
[TBL] [Abstract][Full Text] [Related]
8. An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck.
Pinette A; McMichael E; Courtney NB; Duggan M; Benner BN; Choueiry F; Yu L; Abood D; Mace TA; Carson WE
Cancer Immunol Immunother; 2019 Aug; 68(8):1379-1389. PubMed ID: 31338557
[TBL] [Abstract][Full Text] [Related]
9. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
[TBL] [Abstract][Full Text] [Related]
10. Targeting CD137 enhances the efficacy of cetuximab.
Kohrt HE; Colevas AD; Houot R; Weiskopf K; Goldstein MJ; Lund P; Mueller A; Sagiv-Barfi I; Marabelle A; Lira R; Troutner E; Richards L; Rajapaska A; Hebb J; Chester C; Waller E; Ostashko A; Weng WK; Chen L; Czerwinski D; Fu YX; Sunwoo J; Levy R
J Clin Invest; 2014 Jun; 124(6):2668-82. PubMed ID: 24837434
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid.
Kumai T; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Kobayashi H
Head Neck; 2016 Mar; 38(3):410-6. PubMed ID: 25352398
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.
Taylor RJ; Saloura V; Jain A; Goloubeva O; Wong S; Kronsberg S; Nagilla M; Silpino L; de Souza J; Seiwert T; Vokes E; Villaflor V; Cohen EE
Cancer Immunol Res; 2015 May; 3(5):567-74. PubMed ID: 25769300
[TBL] [Abstract][Full Text] [Related]
13. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.
Trivedi S; Srivastava RM; Concha-Benavente F; Ferrone S; Garcia-Bates TM; Li J; Ferris RL
Clin Cancer Res; 2016 Nov; 22(21):5229-5237. PubMed ID: 27217441
[TBL] [Abstract][Full Text] [Related]
14. An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma.
Temam S; Spicer J; Farzaneh F; Soria JC; Oppenheim D; McGurk M; Hollebecque A; Sarini J; Hussain K; Soehrman Brossard S; Manenti L; Evers S; Delmar P; Di Scala L; Mancao C; Feuerhake F; Andries L; Ott MG; Passioukov A; Delord JP
Ann Oncol; 2017 Nov; 28(11):2827-2835. PubMed ID: 28950289
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Epidermal Growth Factor Receptor Can Counteract the Inhibition of Natural Killer Cell Function Exerted by Colorectal Tumor-Associated Fibroblasts.
Costa D; Venè R; Benelli R; Romairone E; Scabini S; Catellani S; Rebesco B; Mastracci L; Grillo F; Minghelli S; Loiacono F; Zocchi MR; Poggi A
Front Immunol; 2018; 9():1150. PubMed ID: 29910806
[TBL] [Abstract][Full Text] [Related]
16. Anti-epidermal growth factor receptor (EGFR) antibodies overcome resistance of ovarian cancer cells to targeted therapy and natural cytotoxicity.
Gottschalk N; Kimmig R; Lang S; Singh M; Brandau S
Int J Mol Sci; 2012; 13(9):12000-12016. PubMed ID: 23109896
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL
J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189
[TBL] [Abstract][Full Text] [Related]
18. Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy.
Lattanzio L; Denaro N; Vivenza D; Varamo C; Strola G; Fortunato M; Chamorey E; Comino A; Monteverde M; Lo Nigro C; Milano G; Merlano M
Cancer Immunol Immunother; 2017 May; 66(5):573-579. PubMed ID: 28197666
[TBL] [Abstract][Full Text] [Related]
19. A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.
Bertino EM; McMichael EL; Mo X; Trikha P; Davis M; Paul B; Grever M; Carson WE; Otterson GA
Mol Cancer Ther; 2016 Sep; 15(9):2244-50. PubMed ID: 27458141
[TBL] [Abstract][Full Text] [Related]
20. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
